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Abstract
Background Trigeminal neuralgia (TN) is a serious health
problem, causing brief, recurrent episodes of stabbing or burn-
ing facial pain, which patients describe as feeling like an elec-
tric shock. The consequences of living with the condition are
severe. There is currently no cure for TN and management of
the condition can be complex, often delayed by misdiagnosis.
Patients’ qualitative experiential accounts of TN have not
been reported in the literature. Capturing subjective experi-
ences can be used to inform the impact of the condition on
quality of life and may contribute to a better understanding of
current clinical practice with the aim of improving patient
care.
Methods Participants with TN (n=16; 11 female), including
those who have and have not undergone surgical intervention(s),
took part in one of four focus groups. We conducted a thematic
analysis within an essentialist framework using transcripts.
Results The impact of TN and treatment on the lives of par-
ticipants emerged as four predominant themes: (1) diagnosis
and support with TN, (2) living in fear of TN pain, (3) isola-
tion and social withdrawal, and (4) medication burden and
looking for a cure. Each theme is discussed and illustrated
with extracts from the transcripts.
Conclusions Key issues to address in the management of pa-
tients with TN include continued delays in diagnosis, persis-
tent side effects from medication, and a lack of psychological
support. Developing strategies to enhance the management of
patients with TN, informed by a biopsychosocial approach
and multidisciplinary team working, is essential to enhancing
the provision of current care.
Keywords Trigeminal neuralgia . Medication . Surgery .
Management . Qualitative research
Introduction
Trigeminal neuralgia (TN) is a serious health problem, causing
brief, recurrent episodes of stabbing or sharp facial pain, which
patients describe as feeling like an electric shock [10]. Attacks
can be triggered by any kind of movement or touch; they can
occur at numerous intervals or continuously throughout the day
[27]. Trigeminal neuralgia is rare, and hence it is difficult to
obtain high-quality epidemiological data. Data from GP prac-
tices based in the United Kingdom (UK) outlined an inci-
dence of 8 per 10,000 people per year and a lifetime
prevalence of 0.7 per 100,000 people per year [15]. The
consequences of living with the condition are severe.
Often patients live in fear of pain, with daily functioning
disrupted and quality of life impaired [26], typically pre-
senting with higher levels of anxiety and depression [16].
There is currently no cure for TN and management of the
condition can be complex, often delayed bymisdiagnosis. The
lack of any objective testing for TN remains a significant
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clinical problem, impairing clinical research [11]. Patients with
orofacial pain may present to their dental practitioner where the
origin is unclear, with pain subsequently treated as relating to
teeth or surrounding tissue [12]. Once diagnosed, medication is
often the first-line treatment for TN patients. Carbamazepine is
recognized as the drug of choice [18, 27]. Pain severity compels
many patients to use much higher doses, leading to significant
cognitive and motor function side effects [14, 25]. A number of
surgical management options are available for TN, but are
typically only offered when medications fail or side effects
are too severe [21]. One procedure, microvascular decompres-
sion, aims to preserve trigeminal nerve function, with all other
procedures deemed destructive or ablative [27]. The effective-
ness, mortality rates, and morbidities of these procedures are
summarized in Table 1 (based on national guidelines) [6, 9, 19].
Patients’ qualitative experiential accounts of TN have not
been reported in the literature, but they could be used to report
the impact of the condition on quality of life and may contrib-
ute to a better understanding of current clinical practice with
the aim of improving patient care. While existing accounts of
the patient’s journey through TN exist [26, 29], this is the first
reported qualitative study into the experience of TN and the
impact of treatment by patients diagnosed with TN.
Methods
Participants
Participants with TN (n=16; 11 female), including those who
have and have not undergone surgical intervention(s), took
part in the study. Variation in the use of medication(s) to man-
age symptoms was identified across participants (see Table 2).
The duration of time since initial experience of TN symptoms
was very short for three participants, but more experienced a
long delay in diagnosis with some lasting up to 10 years.
Despite most participants (n=13) having received surgery, a
number (n=5) were also continuing to use medication.
Design
Capturing subjective experiences of the pain sufferer using a
qualitative approach can make important contributions to evalu-
ating and improving practice [17]. Four focus groups comprising
2–5 participants were completed, each lasting between 1 h 20min
and 2 h. The discussions were facilitated by two experienced
qualitative health researchers with expertise in psychology (MA,
MT). Focus groups were utilized because they do not assume
pre-existing opinions on a particular topic, yet enable elicitations
of opinions, ideas, and beliefs in a group setting. The researchers
were therefore able to gain a better insight into both the common
and diverse range of experiences of those living with TN.
Participants and recruitment
Participants were identified from one neurosurgery depart-
ment database. The clinical team identified participants aged
>17 years, with a diagnosis of TN and capacity to consent
themselves into the study from a list of outpatients from
12 months prior to the start of the study. A maximum variance
sampling approach was used, intended to capture heterogene-
ity across participants. We sampled patients to ensure that
Table 1 Surgical treatments for trigeminal neuralgia
ytidibroMytilatroM)%(eerfniapdetroperstneitaPerudecorP
2.0)09(mret-gnoLnoisserpmocedralucsavorciM –0.4 (%) Major health problems, such
as infarcts or hematoma
major surgery, non-destructive technique to decompress
the trigeminal nerve, preserving its normal function
ssolyrosneS)08(raey1
ssolgniraeH)57(sraey3
sitigninemcitpesA)37(sraey5
Palliative destructive procedures (radiofrequency
thermocoagulation (RFT), glycerol injection
(GI) and percutaneous balloon compression (PBC))
Post–procedure (GI and PCB) (90) Low Sensory loss
ablative technique, penetrating the trigeminal ganglion
to selectively destroy nerve fibres
ssenbmunlaenroC
)86(raey1
3 years (54–)46
istitareK
saisehtsesyD
)05(sraey5
Anesthesia dolorosa
Stereotactic radiosurgery (Gamma Knife® surgery) Post-procedure (90) Nil Delayed pain relief
non-invasive procedure focusing low intensity
radiotherapy at specific areas of trigeminal nerve tissue
snoitacilpmocyrosneS)96(raey1
aisehtsearaP)25(sraey3
Facial hypoesthesia
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we captured those with experience of a longer-term impact of
TN (at least 2 years post-intervention) and those who have
experienced recent surgery (in the last 6 months) or had sur-
gery planned. All eligible participants were sent an informa-
tion pack via post, which explained the purpose of the study,
and contained an invitation letter.
A total of 40 invitations were issued. Those interested in
participating could contact the research team via phone or
using the response form and prepaid envelope included in
the pack. A member of the research team contacted interested
parties to arrange a suitable date for a focus group. The focus
groups used a topic guide informed by research literature on
the side effects of TN medication and experience of the clin-
ical team. The topic guide asked about participants’ experience
of TN, medication used, and any side effects (e.g., cognitive,
behavioral), alongside the impact on daily living (e.g., family
life, social life, employment). Focus groups were audio record-
ed and took place at the University of Leeds. Ethical approval
was provided by the National Research Ethics Service
Committee for Yorkshire & the Humber–Leeds Central, re-
search ethics committee (reference number 12/YH/0394).
Data analysis
We conducted a thematic analysis within an essentialist frame-
work [5], which rests on the assumption that participants de-
scribed personal experiences, perceptions and understandings
of living and coping with TN and treatment provision. Each
focus group was transcribed verbatim. Participants were of-
fered the opportunity to review the transcripts but none took
up this offer. Transcripts were read several times and the audio
recording of each transcript listened to simultaneously. The
transcripts were summarized in written notes to assist a thor-
ough understanding of each participant’s experiences.
Categories were identified and condensed in order to retain
original expressions, and each category given a label. Three
Table 2 Overview of participant demographics and treatment history
Demographics Treatment history
Current drug management Previous surgical procedures
Focus group Participant Sex Age Year of diagnosis C G T P L Other GK MD PM
1 1 M 68 2009 + X X
2 F 65 1998 O O X
2 3 F + 1996 O +
4 F 79 1998 XX
5 F 45 2004 O Pa; I X
6 F 77 2007 O O XX
3 7 F 70 1997 O O XX
8 M 66 2011 X X
9* M 60 2011 + +
10 F 70 1999 + X
11* F 79 1988 O O X XXXXXX
4 12 F 54 2011 X
13 F 70 2011 X X
14 M 67 2010 X X
15 F 72 2011 XX
16 M 74 2007 +
Participant:
* = participant has multiple sclerosis
+ = participants did not want to provide this information
O = participant reported current medication at time of focus group
X = each ‘X’ represents completion of procedure. Multiple use indicates number of times procedure was completed
Medical management:
C carbamazepine, G gabapentin, T tramadol, P pregabalin, L lamotrigine, Pa paracetamol, I ibuprofen
Surgical management:
Gamma knife (GM) = stereotactic radiosurgery using the gamma knife; microvascular decompression (MD) = microvascular decompression involving
a craniectomy; percutaneous methods (PM) = radiofrequency thermocoagulation, glycerol rhizolysis, balloon compression, or local avulsion and
cryotherapy of the peripheral branches
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researchers were involved in data analysis. One researcher
coded all transcripts; the other two reviewed all transcripts
and coded sections of the data to ensure consistency in coding.
All three met and discussed the development of the thematic
themes and write up. NVivo 9 software (QSR International
Pty Ltd, Australia) was used for carrying out further coding
and facilitating thematic analyses. Common codes were cre-
ated by comparing content across all four focus groups in
order to create common codes relating to the impact of TN
on quality of life. The end point of the analysis was to illustrate
each theme by means of representative quotations from the
data.
Results
The impact of TN and treatment on the lives of participants
emerged as four predominant themes [1]: diagnosis and sup-
port with TN [2], living in fear of TN pain [3], isolation and
social withdrawal, and [4] medication burden and looking for
a cure. Each theme will be discussed and illustrated with ex-
tracts from the transcripts collated in Table 3, with reference to
relevant quotes indicated in the text.
Diagnosis and support with TN
This theme describes the diagnosis and support provided for
TN. Most participants reported a delay in an accurate diagno-
sis alongside difficulties in adjusting to the diagnosis of TN.
Participants described the severity of TN pain and their needs
for health professional support during symptomatic episodes.
Misdiagnosis or extended exploratory investigations (e.g.,
dental work) occurred for most participants prior to receiving
an accurate diagnosis. This was viewed as a significant barrier
to accessing appropriate care resulting in many ineffective
interventions. The theme also describes the impact of se-
vere pain experienced with the condition (ref 1 and 2).
Participants often accessed standard treatments but they
reported that they still experienced pain, which they
found imposed significant limitations on their daily lives.
As well as constantly feeling fatigued, participants also
expressed a sense of loss (ref 3 and 4).
These descriptions illustrate the distress that is a common
consequence of TN. One reason for this is that participants
become overwhelmed by the severity of the pain, and associ-
ated difficulties, and so withdraw, socially. For one partici-
pant, it is difficult to halt feelings of pessimism at those times
(ref 5). Another participant indicated feelings of anger and
resentment at having TN. She momentarily implicates herself,
as if pondering whether she is in some way responsible for her
illness (ref 6).
The analogy of being suddenly struck in the face or the
mouth was used by many participants to describe the onset
of episodes of debilitating pain that last for varying lengths of
time and recur in phases, before easing (ref 7). Because of the
sudden and severe nature of TN pain, participants reported a
need for urgent referral to their consultant, when they became
symptomatic (ref 8). This would be the preferred pathway,
rather than routine appointments, when asymptomatic.
Participants’ accounts illustrate the considerable burden the
sudden nature of TN pain imposes on participants. Between
attacks, participants were fearful that the pain could return at
any time, positioning them as suffering from pain and the fear
of pain.
Living in fear of TN pain
This theme captures the individual impact of TN on the lives
of participants and the disruption it causes as they try to ne-
gotiate daily life. Addressing aspects of quality of life, sub-
themes relating to personal care, diet, impact on emotions,
relationships with family and friends, were discussed in all
four focus groups.
Participants reported a range of avoidance behaviors, af-
fecting the face, since the onset of TN. Fear of pain episodes
prevented participants from engaging in aspects of personal
care, which they had experienced as pain stimuli (ref 9 and
10). Other participants, however, expressed the attitude that
they would continue trying to lead their lives as normal, even
with the potentially disruptive nature of their illness (ref 11).
Despite being determined to continue as normal, participants
were forced to make adjustments in important areas of their
lives. Eating presents a major problem in TN and participants’
reports highlighted a dilemma which placed them between
needing to avoid chewing—in order to prevent pain—and
patterns of disordered food and drink consumption, which
put participants at risk of nutrient deficiency. While one par-
ticipant relied on liquidized food, another adopted an extreme-
ly restricted diet (ref 12). Other participants reported including
alcohol in their diet, to self-medicate and to help them cope
with the pain (ref 13). Participants’ difficulty eating, while in
pain, was revealed as anxiety-provoking and as having impli-
cations for wider social interaction (ref 14).
Isolation and social withdrawal
Emotional difficulties, manifested in feelings of isolation and
withdrawal from social interaction, were reported by partici-
pants in all four groups. Often social isolation arose from
decisions by participants to withdraw as a direct consequence
of pain, or fear of pain. The descriptions of two participants
illustrated experiences of social anxiety (ref 15 and 16).
Depressive symptoms were also indicated by two partici-
pants, the second, awaiting surgery, who made explicit the
extent of their emotional distress (ref 17 and 18). Families
and friends have an important effect on the well-being of
Acta Neurochir
Table 3 Quotations extracted from transcripts
Theme Reference Text, participant, and participant sex (three dots (…) indicate that text has been omitted)
Diagnosis and support with
TN
1 I started about 10 years ago, the first 2 years they were diagnosing me with sinus problems.
FG3, female
2 I had all my fillings taken out and put back in and teeth taken out… I had Botox… no results at all until they
suddenly decided that it was TN… FG2, female
3 I could lie down and go to sleep now; it’s a real problem of fighting the tiredness all day long. FG3, male
4 When you’re in that pain, you know, your life is just wiped out… FG3, female
5 …once you start getting low like that, when the tears start, it’s very hard to come out of it because you’re on a
spiral down… FG2, female
6 It’s like....I always feel…I’ve got a demon sitting onmy shoulder (laughter)…What have I done?…It’s as if
somebody has just hit you in the face for no reason whatsoever and you just want to hit back, you know.
FG4, female
7 To me, it’s like someone had a knife and just kept going [stabbing] in to part of my face all the time.… I
didn’t have minutes of the day when it wasn’t there. FG2, female
8 … anybody with TN, when it gets to the stage where they[we] can’t talk, we need to see a [consultant]
surgeon as quickly as possible… FG1, female
Living in fear of TN pain 9 I don’t clean my teeth a lot because I’m scared to death of setting it [the pain] off. FG3, male
10 I couldn’t lie down, the covers touching [the face] set it off, so I didn’t sleep or I had to sleep in an upright
position. FG2, female
11 I’m in pain with it, but I have to keep going, otherwise I’m giving in to it… FG4, female
12 I lost two stones because I couldn’t eat; I used to live on Maltesers and full cream milk…that was my diet. I
could put Maltesers in my mouth and slowly let them dissolve… FG1, male
13 …a couple of whiskies…that seemed to make the medication work better… FG3, female
14 I couldn’t even have my tea in front of my children or my husband because I felt I looked like a freak.…
you’re in pain and feel like you’re contorted. FG2, female
Isolation and social
withdrawal
15 I just got a personality change and was very sort of serious and quiet, I can’t explain it, all my friends
noticed… I was like a zombie. FG3, female
16 I wouldn’t do social things, in case it [the pain] started while I was out… FG2, female
17 If I couldn’t get the pills I would commit suicide. FG3, male
18 I would probably have put a bullet through my brains because the pain was so intense. FG2, female
19 Imagine, it’s your daughter’s… birthday party, you can’t speak, and you can’t eat, every time you try to
speak [it’s like] someone smacks you straight in the mouth… so you’re not going to go are you? FG1,
male
20 I used to pick up my grandchildren and give them a bear hug, but because the pain gradually got worse over
the years, I had to stop doing it, and that definitely put a distance between us. FG3, female
Medication burden and
looking for a cure
21 I was relying on those drugs because I believed it was taking some of the pain away and was scared
to come off them, in case it was, but still I was in severe pain… too many drugs and still in pain.
FG2, female
22 I’m taking amitriptyline and pregabalin and I had gabapentin before that and co-codomol but they don’t do
anything, it’s [pain] just there all the time… FG3, female
23 Well I actually overdose on gabapentin and I take 1200 mg three times a day plus…when you’re in that pain
you’ll take anything. FG3, male
24 I’ve done maximum, you know,…couldn’t bear it anymore, and I have actually I must admit, I have…
carbamazepine, actually, and pain killers… I had it so bad one night… FG4, female
25 [the doctor] said to me: BYou’re toxic you’ve got far too much carbamazepine in you… I’d also
started with eczema, which the dermatologist thought was …a reaction to the carbamazepine.
FG2, female
26 Yes, that [Tegretol retard] did inflame my liver; I was really poor with it, so I came off of it quite quickly and
then, of course, I was in agony because I was in-between pills… FG3, female
27 When I go onto the drugs it normally gets rid of the pain… [but] the drugs exacerbate all my MS [multiple
sclerosis] symptoms… so, If I’m on a preventive dose I don’t go out of the house, if I’m on the
medication, I’m stuck there. FG4, female
28 … I stopped taking them [the tablets] like that, I suffered for it, but… I thought: BI’m sick of taking
tablets…^ Taking that many tablets you forget whether you’ve taken them or not. So I came straight off
them… FG1, male
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participants as they manage their illness. Most participants
reported that relatives were supportive, but pain severity in-
duced isolation and made social interaction difficult, even
with family (ref 19 and 20). Avoidance of certain aspects of
daily living and of social situations is presented as central to
the impact of TN. Despite the strength of relationships within
families, the pain and unpredictability of the condition cause
difficulties in adjustment, for all parties.
Medication burden and looking for a cure
Participants in all four focus groups reported limitations in
pharmacological management. They identified a range of is-
sues that characterized treatment failure, and as can be seen by
Table 2, over time, most had experienced several changes in
medication. The majority expressed a sense of being
overwhelmed by the side effects of drug treatment, in addition
to continuing pain (ref 21 and 22). Many participants directed
the problem of pain towards attempts to self-manage medica-
tion, continually assessing their needs and fluctuating between
dosages in attempts to establish an effective regimen and exert
a degree of control over their pain. Two participants revealed
that they had intentionally over-medicated because of pain
severity (ref 23 and 24).
For most participants, the attempt to self-manage medica-
tion involved a constant struggle to balance their need for
optimal pain relief against their wish to avoid dose-related side
effects. All participants reported extreme tiredness, with some
developing additional health issues (ref 25 and 26).
Even when drug intake produced anticipated benefits, par-
ticipants still encountered challenges to their quality of life,
with increased treatment side effects being accepted as trade-
offs for achieving pain relief from TN (ref 27). Participants
reported experiencing long-term medication use to be as bur-
densome as living with the chronic nature of TN itself. Many
felt forced to make difficult choices about whether to endure
side effects or risk the pain associated with TN (ref 28).
When taking chronic pain medication, participants encoun-
tered different impacts that were defined by their initial expe-
riences of treatment. Participants often felt overwhelmed by
the drugs they were prescribed, they worried they would not
work, and experienced distressing side effects and associated
health issues. Participants reported a number of medication-
related cognitive impairments, which caused additional diffi-
culties in everyday functioning. Employment was one of the
key areas in which participants were affected by the debilitat-
ing combination of chronic pain and side effects of medica-
tion. One participant reported leaving his job after an accident
caused him to question the safety of his work (ref 29). A
participant reported being subjected to accusations of drug
addiction when side effects of pain medication caused fatigue,
along with speech and mobility problems (ref 30). Another
participant reported that medication side effects affected her
performance on accountancy computing tasks at work. The
difficulties she encountered led her to leave her job (ref 31).
Table 3 (continued)
Theme Reference Text, participant, and participant sex (three dots (…) indicate that text has been omitted)
29 I gave up doing gas work, I couldn’t guarantee that I could concentrate on it enough to do it… I chopped [off]
the ends of three fingers, I wasn’t concentrating… I was thinking about the pain instead of what I was
doing… FG3, male
30 I had people accusing me of being a Bdruggie^…work colleagues saying: Bthere’s nothing wrong with you,
you’re just a druggie^, you’re on drugs… FG2, female
31 I just couldn’t keep up, my reactions had slowed down… it would feel as if I were being pushed out, so I just
gave my notice. FG1, female
32 I did run into the back of three cars while driving… I shouldn’t have been driving but I was reluctant to give
up work and work involved travel. FG2, female
33 I couldn’t calculate, I lost my mental arithmetic, it disappeared I just could not think…So yeah it did affect
me…FG3, female
34 Simple everyday things like that I should have known had just gone and it didn’t matter how I tried I just
couldn’t bring them back. FG2, female
35 I have a feeling of swaying all the time, as if I was going to sort of fall over in slow motion… FG3, female
36 I’m sort of not connecting between my brain and what I’m doing, and sometimes I can write and think…no
problem, other times I can’t… FG1, female
37 …surgery, it was never mentioned for me when it [the pain] was bad…when I was kind of drug-controlled.
FG2, female
38 I just wanted to cut down on the medication… it [surgery] did that… It got rid of the pain… it’s just
uncomfortable now. I can live with uncomfortable. FG2, female
39 …once I had this done, it was wonderful, all the pain had gone I was back to normal, it’s really really nice…
when you can’t, talk, eat, socialize, it takes a lot way from you.. FG1, male
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Difficulties caused by side effects were broad. Driving was
an environment in which participants experienced concentra-
tion difficulties. One participant reported that she had been
suffering side effects when she caused several minor driving
collisions (ref 32). Mental arithmetic was more difficult for
participants when they were taking medication (ref 33).
Memory was another key area of difficulty. Three reported
problems with recall of numbers and also recall of words
and names. Additionally, skills such as following a knitting
pattern (ref 34) were impaired. Two participants reported mo-
tor function difficulties, which affected their balance. The
same participants experienced problems with fine motor con-
trol, with both describing how they were often unable to co-
ordinate their actions for handwriting (ref 35 and 36).
As all focus group participants had been on medication for
significant periods of time, they were all able to identify ways
in which the high doses they used had affected their cognitive
functioning. Some participants had undergone at least two
surgical procedures, hoping to be cured. Resolution of TN is
challenging but surgery can improve pain, and all participants
reported less medication use, post-surgery. While not
completely off medication, because of fears of pain recur-
rence, participants reported less tiredness and better function-
ing. Although participants had experienced negative effects
whilst using medication, they had been compliant because
surgical interventions had not been offered (ref 37). Having
taken significant doses of medication for long periods of time,
participants were also knowledgeable about medication side
effects and have realistic expectations of surgery (ref 38).
Where surgical procedures had been performed, positive
outcomes were reported. For example, participants who had
undergone GK treatment reported benefits to their everyday
lives. In contrast with their former feelings of isolation, par-
ticipants valued the symptom relief achieved by this procedure
as enabling them to re-engage with aspects of life that they
considered important (ref 39).
Discussion
These accounts contribute the first qualitative study into the
impact of living with TN, outlining the impact of TN pain and
subsequent medications on the social lives of participants. The
experience described by participants is one of uncertainty and
fear. In line with narratives provided around the experience of
TN [26, 29] participants drew on experiences of sudden, crip-
pling pain. There was also marked variation in lengths of time
in which patients did not know the cause of their pain before
receiving a diagnosis. Most participants presented to dentists,
where knowledge gaps in chronic orofacial pain have been
identified in both general dental practitioners and dental spe-
cialists [2]. This, teamed with the lack of any objective testing
for TN may in part explain the seemingly random likelihood
of receiving an accurate and timely diagnosis. For patients
with multiple sclerosis, a shorter duration to diagnosis was
discussed, perhaps aided by a 20-fold higher presence of TN
in this patient group than in the general population and recog-
nition of the condition by neurologists [20].
The study recruited participants through a large neurosur-
gery department in the north of England. The experiences of
services by participants in this study are limited to the region
covered by the department, albeit a large regional tertiary re-
ferral centre offering a full range of surgical management op-
tions. Participants were a subgroup of TN patients interacting
with a neurosurgeon via an outpatient clinic and further ex-
ploration of patient management across a range of sites would
contribute to a broader understanding of service provision for
patients with TN. The accounts depicted in this study have
arisen from analysis by two psychologists (MA and MT) with
involvement of a multi-disciplinary team including a neuro-
surgeon and applied health researchers. We made ensured in-
volvement of additional researchers in the focus group and
analysis process (HG, FM) to enhance the rigor and transpar-
ency of analysis.
The narratives of participants serve to align the responses
of TN patients with individuals who report chronic pain. The
far-reaching effects and solitary experience of chronic pain
[24] and impact of pain on the quality of social and working
lives [23] were reported. Dietary and behavior changes as an
approach to avoiding a wide variety of stimuli were also re-
ported. Such avoidance both directly (e.g., physical activities)
and indirectly (e.g., social activities) has been documented for
those with chronic pain [3]. Participants’ reported approaches
to managing pain are not abnormal, but aligned with people
managing severe pain in their lives.
The use of medication for pain by participants with TNwas
often described as prophylactic, taken regularly and increased
when pain occurred. The severity of the pain meant that pa-
tients would persist for long periods of time using medication,
despite all drugs having the potential to result in neurological
side effects such as drowsiness, ataxia, and diplopia at
higher doses [27]. Pain guidelines typically emphasize self-
management approaches, but provide little information on
how to facilitate it [7]. Specialist services such as pain clinics
have demonstrated that supporting medication use can improve
self-management of pain medication [8]. While many partici-
pants in this study had close interaction with TN specialists,
their lives continued to be affected by the condition with reports
of underdosing and overdosing of prescribed pain medication
as part of a process for seeking effective management of their
pain. At one center the research team uses a clinical nurse
specialist with prescribing rights to provide further advice about
medication which has been evaluated very positively.
For TN, defining what good management is, and what can
be expected from pharmacological and surgical management
may support patient decision making from diagnosis. An
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attempt to look at how patients make decisions was hampered
by lack of good quality evidence but suggested patients pre-
ferred surgical options [22]. While pharmacological manage-
ment is the first line treatment for TN [27], many participants
reported multi-pharmacy, alongside impaired cognitive and
motor skills and subsequent consequences (work-related inju-
ries and road accidents). Detection of these is difficult, as they
are not picked up on routine medical reviews. For participants
who had experienced pharmacological and surgical treat-
ments, low mood, suicidal ideation, anger and self-blame,
alongside diminished relationships with friends and family
were reported. Psychological treatments are not a routine com-
ponent in the treatment of TN, although they feature in the
management of complex orofacial pain conditions, such as
temporomandibular joint disorders, for which cognitive be-
havioral therapies have been shown to be effective [1, 13].
The research team has piloted a cognitive behavior program
which includes a talk by a medical expert exclusively for TN
patients to improve their coping strategies’ and it is currently
being evaluated. Surgical interventions were offered to partic-
ipants who had been experiencing pain that was refractory to
pharmacological management, or where quality of life was
significantly compromised. The place of surgical options later
in the care pathway requires many patients to experience
months and years of complex management of their pain, high
levels of pain medication, and problematic side effects. Some
centers do offer early neurosurgical opinion so patients are
more aware of the options open to them and it enables the
pathway to be accessed quicker in an emergency [28].
Alongside this, research is exploring new approaches to the
management of severe cases such as the creation of specialist
regional centers for chronic orofacial pain [4].
This study highlights the considerable impact on quality of
life of both unpredictable episodic pain and complications
from treatment which can occur after both pharmacological
and surgical intervention. Developing strategies for address-
ing these key issues in the management of patients with TN
are essential to enhance the provision of current care and re-
quire a more biopsychosocial approach using multidisciplin-
ary teams.
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